- Home
- EDSA vs QNCX Comparison
EDSA vs QNCX Comparison
Compare EDSA & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDSA | QNCX |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 6.9M |
| IPO Year | 2018 | 2019 |
Fundamental Metrics
Financial Performance| Metric | EDSA | QNCX |
|---|---|---|
| Price | $5.22 | $1.25 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | 950.2K | ★ 67.1M |
| Earning Date | 05-13-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.72 | $0.08 |
| 52 Week High | $9.37 | $4.55 |
Technical Indicators
Market Signals| Indicator | EDSA | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 47.46 | 79.65 |
| Support Level | $4.94 | $0.10 |
| Resistance Level | $9.06 | $1.99 |
| Average True Range (ATR) | 0.76 | 0.07 |
| MACD | -0.23 | 0.15 |
| Stochastic Oscillator | 9.84 | 84.48 |
Price Performance
Historical ComparisonAbout EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.